Granada, Spain

Ibon Gutierro Aduriz

This inventor holds 30 USPTO granted patents and 6 published patent applications, plus 8 CIPO patents and 10 EPO patents, primarily in Injectable Pharmaceutical Formulations. Top assignees: Laboratorios Farmaceuticos Rovi S.a., Laboratories Farmacéuticos Rovi, S.a., Laboratorios Farmacéticos Rovi, S.a.. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ibon Gutierro Aduriz. Retrieved from https://idiyas.com/inventor/ibon-gutierro-aduriz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 30 

% Patents Active = 90.0

 

 

Average Co-Inventor Count = 2.1

ph-index = 9

Forward Citations = 187(Granted Patents)


Location History:

  • Granada, ES (2012 - 2024)
  • Madrid, ES (2018 - 2024)

Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Injectable Composition
Depot Composition
Antipsychotic Formulation
Aromatase Inhibitor
Pharmaceutical Container
Aseptic Filling
Risperidone
Paliperidone
Glycosaminoglycans
Nuclear Magnetic Resonance
Pharmaceutical Dosage Forms
Active Compounds
30 patents (USPTO):Explore Patents

Title: Innovations by Ibon Gutierro Aduriz: Pioneering Pharmaceutical Solutions

Introduction: Ibon Gutierro Aduriz is a prominent inventor based in Granada, Spain, with an impressive portfolio of 28 patents. His work primarily focuses on pharmaceutical innovations that enhance drug delivery and administration methods. Aduriz’s contributions are vital in the field of medicinal chemistry, addressing critical needs in therapeutic applications.

Latest Patents: One of Ibon Gutierro Aduriz’s latest innovations is an injectable composition designed to form an in situ intramuscular implant. This biodegradable thermoplastic polymer composition, utilizing polylactic acid (PLA), includes a solvent and drug. Upon administration, the implant delivers a specific dose of 0.1-2 milligrams of a nonsteroidal aromatase inhibitor daily over a period ranging from six months to one year, offering a robust solution for patients requiring such treatment.

Another significant patent involves a sterile procedure for filling solids into pharmaceutical containers and sealing them under sterile conditions. This procedure pertains to various containers, such as syringes, vials, and capsules, which can be filled with powders, granules, or microparticles. The methodology he developed minimizes adherence of materials to container surfaces during the filling process, ensuring airtight seals and accurate dosing in pharmaceutical applications.

Career Highlights: Ibon Gutierro Aduriz’s career includes substantial contributions while working at Laboratorios Farmacéuticos Rovi, where he has been instrumental in the development of innovative solutions in the pharmaceutical sector. His expertise in drug formulation and delivery systems has established him as a key figure in this industry.

Collaborations: Throughout his career, Ibon Gutierro Aduriz has collaborated with notable professionals such as Maria Teresa Gomez Ochoa and Guillermo Franco Rodriguez. These partnerships have facilitated the advancement of his inventions and have contributed significantly to various projects within the pharmaceutical landscape.

Conclusion: Ibon Gutierro Aduriz exemplifies the spirit of innovation in the pharmaceutical field with his impressive array of patents. His work not only advances the capabilities of drug delivery systems but also addresses critical healthcare needs, affirming his status as a valuable inventor in contemporary medicine. Through his continued efforts, Aduriz is set to influence future developments in pharmaceutical technologies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…